| Bioactivity | Ceftezole is an α-Glucosidase inhibitor with an IC50 and a Ki of 2.1 μM and 0.578 μM, respectively. |
| Target | IC50: 2.1 μM (α-Glucosidase)Ki: 0.578 μM (α-Glucosidase) |
| Invitro | In in vitro α-Glucosidase assays, Ceftezole is shown to be a reversible, non-competitive inhibitor of yeast α-glucosidase with a Ki value of 5.78×10-7 M when the enzyme mixture is pretreated with ceftezole[1]. |
| In Vivo | Using an in vivo streptozotocin-induced mouse model, blood glucose levels are confirmed to be decreased by 30% 20 min after Ceftezole treatment (10 mg/kg/day). Expression levels of glycogen synthase kinase-3, peroxisome proliferator-activated receptor-γ, and uncoupling protein-3 mRNA are also slightly decreased compare to controls following Ceftezole treatment[1]. |
| Name | Cefetrizole |
| CAS | 65307-12-2 |
| Formula | C16H15N5O4S3 |
| Molar Mass | 437.52 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lee DS, et al. Ceftezole, a cephem antibiotic, is an alpha-glucosidase inhibitor with in vivo anti-diabetic activity. Int J Mol Med. 2007 Sep;20(3):379-83. |